The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications
Abstract
Since the discovery of the antiprogestin mifepristone, hundreds of similar compounds have been synthesized, which can be grouped in a large family of progesterone receptor ligands. This family includes pure agonists such as progesterone itself or progestins and, at the other end of the biological spectrum, pure progesterone receptor antagonists (PA). Selective progesterone receptor modulators (SPRM) have mixed agonist-antagonist properties, and occupy an intermediate position of the spectrum. These compounds have numerous applications in female health care. Mifepristone is used to terminate pregnancy, and as such is commercially available in many countries. The negative abortion-related image of mifepristone has clearly limited the involvement of the major pharmaceutical companies in the development of PA and SPRM. Many PA and SPRM display direct antiproliferative effects in the endometrium, although with variable actions which seem product- and dose-dependent. This property justifies their use in the treatment of myomas and endometriosis. PA also suppress late follicular development, block the LH surge and retard endometrial maturation, which renders them potential estrogen-free contraceptive drugs. SPRM such as asoprisnil are not as effective in blocking the LH surge and appear to target the endometrium directly and produce amenorrhoea. Interestingly, clinical data show that treatment with these compounds is not associated with hypo-estrogenism and bone loss. The potential clinical applications of these compounds cover a broad field and are very promising in major public health areas. These include emergency contraception, long-term estrogen-free contraception (administered alone, or in association with a progestin-only pill to improve bleeding patterns), myomas (where they induce a marked reduction in tumour volume and produce amenorrhoea) and endometriosis. Further developments might also include hormone replacement therapy in post-menopausal women, as well as the treatment of hormone-dependent tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SPRMs induce amenorrhea without causing a hypoestrogenic state or associated bone loss (Chabbert-Buffet et al., 2005).”
From Endometriosis and nuclear receptors (2019) · cites this paper as Chabbert-Buffet et al., 2005
Citations
Cites
Noyes, R. W., Hertig, A. T., & Rock, J. (1950) · Fertility and Sterility · doi:10.1016/s0015-0282(16)30062-0 · Cited by 2,843
Kastner, P., Krust, A., Turcotte, B., Stropp, U., Tora, L., Gronemeyer, H., & Chambon, P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08280.x · Cited by 1,534
Hall, J. M., & McDonnell, D. P. (1999) · Endocrinology · doi:10.1210/endo.140.12.7179 · Cited by 1,075
Wilcox, A. J., Weinberg, C. R., & Baird, D. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332301 · Cited by 1,070
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
Vegeto, E., Shahbaz, M. M., Wen, D. X., Goldman, M. E., O'Malley, B. W., & McDonnell, D. P. (1993) · Molecular Endocrinology · doi:10.1210/mend.7.10.8264658 · Cited by 760
Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform
Mulac-Jericevic, B., Mullinax, R. A., DeMayo, F. J., Lydon, J. P., & Conneely, O. M. (2000) · Science · doi:10.1126/science.289.5485.1751 · Cited by 704
von Hertzen, H., Piaggio, G., Peregoudov, A., Ding, J., Chen, J., Song, S., Bártfai, G., Ng, E., Gemzell-Danielsson, K., Oyunbileg, A., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11767-3 · Cited by 570
Estrogen receptor (ER) β, a modulator of ERα in the uterus
Weihua, Z., Saji, S., Mäkinen, S., Cheng, G., Jensen, E. V., Warner, M., & Gustafsson, J.-Å. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.5936 · Cited by 507
Cyclic AMP and progesterone receptor cross-talk in human endometrium: a decidualizing affair
Gellersen, B., & Brosens, J. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1780357 · Cited by 436
Research works printed but not linked: 28
- 2001, Cancer Res, 61, 4576
- 2001, Hum Reprod, 16, 72
- 1997, Acta Obstet Gynecol Scand Suppl, 164, 75
- 2002, J Soc Gynecol Invest, 9
- 2003, J Soc Gynecol Invest, 10, 301A
- 1991, Obstet Gynecol, 77, 410
- 2003, Obstet Gynecol, 101, 243
- 1998, J Clin Endocrinol Metab, 83, 4092
- 1999, Recent Prog Horm Res, 291
- 2002, J Clin Endocrinol Metab, 87, 2960, 10.1210/jcem.87.6.8572 · doi:10.1210/jcem.87.6.8572 · Paper page
- 1996, J Clin Endocrinol Metab, 81, 1933
- 1994, Hum Reprod, 9, 202
- 1994, Hum Reprod, 9, 77
- 1998, Mol Endocrinol, 12, 278
- 1998, J Reprod Med, 43, 551
- 1998, Cancer Res, 58, 1860
- 2000, Anticancer Res, 20, 4889
- 1999, J Clin Endocrinol Metab, 84, 2963
- 1993, J Clin Endocrinol Metab, 76, 513
- 1994, Am J Obstet Gynecol, 170, 1623, 10.1016/S0002-9378(12)91826-8 · doi:10.1016/s0002-9378(12)91826-8
- 1987, Bull Cancer, 74, 455
- 1994, J Clin Endocrinol Metab, 78, 440
- 1993, Mol Endocrinol, 7, 1256
- 1993, Mol Endocrinol, 7, 1244
- 1996, Chin J Obstet Gynecol, 31, 624
- 1998, Hum Reprod, 13, 259
- 1998, Zhonghua Fu Chan Ke Za Zhi, 33, 490
- 1999, Mol Endocrinol, 13, 418
Cited by
The Methylation Effect in Medicinal Chemistry
Barreiro, E. J., Kümmerle, A. E., & Fraga, C. A. M. (2011) · Chemical Reviews · doi:10.1021/cr200060g · Cited by 1,017
Uterine fibroid management: From the present to the future
Donnez, J., & Dolmans, M.-M. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw023 · Cited by 780
Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery
Donnez, J., Tatarchuk, T. F., Bouchard, P., Puscasiu, L., Zakharenko, N. F., Ivanova, T., Ugocsai, G., Mara, M., Jilla, M. P., Bestel, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1103182 · Cited by 680
Self-citationProgesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer
Kim, J. J., Kurita, T., & Bulun, S. E. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1043 · Cited by 520
The kisspeptin-GnRH pathway in human reproductive health and disease
Skorupskaite, K., George, J. T., & Anderson, R. A. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu009 · Cited by 500
Metadata
- Authors
- Chabbert-Buffet, N., Meduri, G., Bouchard, P., & Spitz, I. M.
- ORCID
- Bouchard, Philippe
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-05-01
- Volume
- 11
- Issue
- 3
- Pages
- 293-307
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2147700987
- Cited by
- 310
- References
- 156
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 7 · 2023: 3 · 2022: 7 · 2021: 12 · 2020: 11 · 2019: 16 · 2018: 14 · 2017: 23 · 2016: 17 · 2015: 20 · 2014: 23 · 2013: 20 · 2012: 19
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Reproduction Update (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
- Keywords
- selective progesterone receptor modulators, antiprogestins, mifepristone, asoprisnil, uterine fibroids, endometriosis, emergency contraception, amenorrhea, bone loss, hormone replacement therapy, hormone-dependent tumors, abortion
- MeSH terms
- Endometriosis, Estrenes, Female, Gonanes, Humans, Leiomyoma, Norpregnadienes, Oximes, Oxytocics, Progesterone, Receptors, Progesterone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. https://app.cochat.ai/papers/10.1093/humupd/dmi002
- The paper
- Chabbert-Buffet, N., Meduri, G., Bouchard, P., & Spitz, I. M. (2005). Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Human Reproduction Update. https://doi.org/10.1093/humupd/dmi002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.